| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | ibrutinib (Imbruvica®) |
| Formulation | 140mg, 280mg, 420mg, 560mg film coated tablets |
| Reference number | 4547 |
| Indication | As a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 02/08/2022 |
| NICE guidance | TA891: Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia |